Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 2/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11300231 | 0.82 | ALDH1A1 (0.66) | ALDH1A1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL9824160 | 0.82 | ALDH1A1 (0.70) | ALDH1A1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL171719 | 0.82 | ALDH1A1 (0.61) | ALDH1A1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL13114706 | 0.82 | ALDH1A1 (0.61) | ALDH1A1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL6414624 | 0.82 | MEN1 (0.56) | ALDH1A1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL23747754 | 0.81 | LSS (0.78) | RAB9APOLBNPC1LSSMEN1 | |
| SCHEMBL19501389 | 0.81 | SMN1; SMN2 (0.56) | ALDH1A1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL18773733 | 0.81 | AOC3 (0.56) | ALDH1A1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL9824635 | 0.81 | ALDH1A1 (1.00) | ALDH1A1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL10157120 | 0.80 | ALDH1A1 (0.58) | ALDH1A1RAB9AHTTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | claimed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| CN-1239472-C | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2006-02-01 | — | — | CN | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| CN-1441775-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-0200134-B1 | 5,6-Dihydroimidazo[2,1-b]thiazole-2-carboxamide derivatives or salts thereof | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4910315-A | Containing a phenyl substitution | KUMIAI CHEMICAL INDUSTRY CO. (JP) | 1990-03-20 | — | — | US | disclosed |
| US-4736038-A | IMMUNOLOGY | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1988-04-05 | — | — | US | disclosed |
| EP-0200134-A2 | 5,6-Dihydroimidazo[2,1-b]thiazole-2-carboxamide derivatives or salts thereof | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | ALDH1A1 1020/4885RAB9A 3489/4885HTT 1420/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | ALDH1A1 239/4885RAB9A 3358/4885HTT 2477/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | ALDH1A1 239/4885RAB9A 3358/4885HTT 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.